•  
  •  
  •  
  •  

2026-04-20 23:12:21

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • PNB Gilts Limited Reports FY26 Financial Results; Annual Profit at ₹181.62 Crore
  • Bank of Maharashtra Reports Record Net Profit of ₹7,017 Crore for FY26
  • NELCO Limited recommends final dividend of Rs. 1
  • Billionbrains Garage Ventures (Groww) Reports Strong FY26 Results; Net Profit Climbs to ₹20,830 Million
  • Takyon Networks Ltd receives order worth Rs. 1.94 crore

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • USFDA inspection at Somerset facility of Lupin Ltd
  • Aurobindo Pharma receives USFDA Approval for Dextromethorphan Polistirex ExtendedRelease Oral Suspension, 30 mg/5 mL (OTC)
  • Veerhealth Care Limited receives order worth Rs. 616 lakhs
  • USFDA inspection at Cipla Ltd's manufacturing facility in Goa, India
  • Amrutanjan Health Care Expands Portfolio with Strategic Foray into Razors and New Care Solutions
  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Take Solutions announces plans to disrupt the Indian Longevity and Anti-Aging Solutions
  • Lupin Pharmaceuticals, Inc, USA enters into settlement agreement with Humana Inc
  • Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Methotrexate Injection USP
  • Jeena Sikho Lifecare Limited Receives Prestigious NABH Accreditation for Noida Hospital
  • Rubicon Research enters the Indian CNS formulations market with the acquisition of Arinna Lifesciences Ltd
  • Indoco Remedies' testing facility completes US FDA PAI
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alkem launches A to Z Daily, an everyday multivitamin supplement for body and mind
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • CuraTeQ Biologics announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11
  • Granules India Limited completes cGMP Audit at its Chantilly Site

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • PNB Gilts Limited Reports FY26 Financial Results; Annual Profit at ₹181.62 Crore
  • Bank of Maharashtra Reports Record Net Profit of ₹7,017 Crore for FY26
  • NELCO Limited recommends final dividend of Rs. 1
  • Billionbrains Garage Ventures (Groww) Reports Strong FY26 Results; Net Profit Climbs to ₹20,830 Million
  • Takyon Networks Ltd receives order worth Rs. 1.94 crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025